Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models
Abstract
1. Introduction
2. Materials and Methods
2.1. Fabrication of Electrospun PCL Nanofiber Sheets
2.2. Drug Release Profile
2.3. Cancer Cell Lines and Reagents
2.4. Animals
2.5. Treatment of Subcutaneous Tumor Models
2.6. Treatment of a Peritoneal Metastasis Model
2.7. Histopathological Examination
2.8. Measurement of Oxaliplatin Concentrations in Blood
2.9. Statistical Analysis
3. Results
3.1. Sustainable Oxaliplatin Release from PCL Sheets
3.2. Antitumor Effects of Oxaliplatin Sheets in a Human Colon Cancer Subcutaneous Xenograft Tumor Model
3.3. Pathological Evaluation of Antitumor Effects by Oxaliplatin in Subcutaneous Tumors and Adverse Effects of Oxaliplatin in the Liver
3.4. Antitumor Effects of Oxaliplatin Sheets in Different Implantation Positions
3.5. Trends in Blood Oxaliplatin Concentrations
3.6. Oxaliplatin Sheets Showed Antitumor Effects in a Human Gastric Cancer Subcutaneous Xenograft Tumor Model
3.7. Effects of Oxaliplatin Sheets in a Mouse Model of Peritoneal Seeding of Gastric Cancer Cells
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
DDS | Drug delivery systems |
PCL | Poly(ε-caprolactone) |
SOS | Sinusoidal obstructive syndrome |
EPR | Enhanced permeability and retention |
PBS | Phosphate-buffered saline |
H&E | Hematoxylin and eosin |
Ki-67 LI | Ki-67 labeling index |
MI | Mitotic index |
AUC | Area under the concentration-time curve |
PLLA | poly(L-lactide) |
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Japanese Gastric Cancer Association Japanese Gastric Cancer Treatment Guidelines 2021 (6th Edition). Gastric Cancer 2023, 26, 1–25. [CrossRef]
- Ajani, J.A.; D’Amico, T.A.; Bentrem, D.J.; Chao, J.; Cooke, D.; Corvera, C.; Das, P.; Enzinger, P.C.; Enzler, T.; Fanta, P.; et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 2022, 20, 167–192. [Google Scholar] [CrossRef]
- Lordick, F.; Carneiro, F.; Cascinu, S.; Fleitas, T.; Haustermans, K.; Piessen, G.; Vogel, A.; Smyth, E.C. ESMOGuidelines Committee Electronic address: Clinicalguidelines@esmoorg Gastric Cancer: ESMOClinical Practice Guideline for Diagnosis Treatment Follow-Up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2022, 33, 1005–1020. [Google Scholar] [CrossRef] [PubMed]
- Benson, A.B.; Venook, A.P.; Al-Hawary, M.M.; Arain, M.A.; Chen, Y.-J.; Ciombor, K.K.; Cohen, S.; Cooper, H.S.; Deming, D.; Farkas, L.; et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 2021, 19, 329–359. [Google Scholar] [CrossRef]
- Cervantes, A.; Adam, R.; Roselló, S.; Arnold, D.; Normanno, N.; Taïeb, J.; Seligmann, J.; De Baere, T.; Osterlund, P.; Yoshino, T.; et al. Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2023, 34, 10–32. [Google Scholar] [CrossRef] [PubMed]
- Hashiguchi, Y.; Muro, K.; Saito, Y.; Ito, Y.; Ajioka, Y.; Hamaguchi, T.; Hasegawa, K.; Hotta, K.; Ishida, H.; Ishiguro, M.; et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2019 for the Treatment of Colorectal Cancer. Int. J. Clin. Oncol. 2020, 25, 1–42. [Google Scholar] [CrossRef]
- Fan, C.Q.; Crawford, J.M. Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease). J. Clin. Exp. Hepatol. 2014, 4, 332–346. [Google Scholar] [CrossRef]
- Yamada, Y.; Higuchi, K.; Nishikawa, K.; Gotoh, M.; Fuse, N.; Sugimoto, N.; Nishina, T.; Amagai, K.; Chin, K.; Niwa, Y.; et al. Phase III Study Comparing Oxaliplatin plus S-1 with Cisplatin plus S-1 in Chemotherapy-Naïve Patients with Advanced Gastric Cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015, 26, 141–148. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Li, F.; Wang, L.; Xiao, M.; Ni, L.; Jiang, S.; Ji, Y.; Zhang, C.; Zhang, W.; Wang, J.; et al. Endoscopic Treatment of Gastroesophageal Variceal Bleeding after Oxaliplatin-Based Chemotherapy in Patients with Colorectal Cancer. Endoscopy 2020, 52, 727–735. [Google Scholar] [CrossRef]
- Schouten van der Velden, A.P.; Punt, C.J.A.; Van Krieken, J.H.J.; Derleyn, V.A.; Ruers, T.J.M. Hepatic Veno-Occlusive Disease after Neoadjuvant Treatment of Colorectal Liver Metastases with Oxaliplatin: A Lesson of the Month. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2008, 34, 353–355. [Google Scholar] [CrossRef] [PubMed]
- Liu, T.; Shen, Q.; Zhou, X.; Shen, X.-; Lai, L.; Hou, X.; Liu, K. Application of Controlled Low Central Venous Pressure during Hepatectomy: A Systematic Review and Meta-Analysis. J. Clin. Anesth. 2021, 75, 110467. [Google Scholar] [CrossRef]
- Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano Based Drug Delivery Systems: Recent Developments and Future Prospects. J. Nanobiotechnol. 2018, 16, 71. [Google Scholar] [CrossRef] [PubMed]
- Hou, J.; Li, C.; Cheng, L.; Guo, S.; Zhang, Y.; Tang, T. Study on Hydrophilic 5-Fluorouracil Release from Hydrophobic Poly(ε-Caprolactone) Cylindrical Implants. Drug Dev. Ind. Pharm. 2011, 37, 1068–1075. [Google Scholar] [CrossRef]
- Niiyama, E.; Uto, K.; Lee, C.M.; Sakura, K.; Ebara, M. Hyperthermia Nanofiber Platform Synergized by Sustained Release of Paclitaxel to Improve Antitumor Efficiency. Adv. Healthc. Mater. 2019, 8, e1900102. [Google Scholar] [CrossRef]
- Yoshida, T.; Kaibori, M.; Fujisawa, N.; Ishizuka, M.; Sumiyama, F.; Hatta, M.; Kosaka, H.; Matsui, K.; Suzuki, K.; Akama, T.O.; et al. Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model. Nanomaterials 2022, 12, 1364. [Google Scholar] [CrossRef] [PubMed]
- Kolinsky, K.; Shen, B.-Q.; Zhang, Y.-E.; Kohles, J.; Dugan, U.; Zioncheck, T.F.; Heimbrook, D.; Packman, K.; Higgins, B. In Vivo Activity of Novel Capecitabine Regimens Alone and with Bevacizumab and Oxaliplatin in Colorectal Cancer Xenograft Models. Mol. Cancer Ther. 2009, 8, 75–82. [Google Scholar] [CrossRef]
- Pourhassan, H.; Clergeaud, G.; Hansen, A.E.; Østrem, R.G.; Fliedner, F.P.; Melander, F.; Nielsen, O.L.; O’Sullivan, C.K.; Kjær, A.; Andresen, T.L. Revisiting the Use of sPLA2-Sensitive Liposomes in Cancer Therapy. J. Control. Release Off. J. Control. Release Soc. 2017, 261, 163–173. [Google Scholar] [CrossRef]
- Zhang, N.; Hao, Y.; Liu, H.; Yu, Q.; Bo, B.; Liang, J. Combined Anti-Cancer Effects of Curcumin and Oxaliplatin on Colon Carcinoma Colo205 Cells Using Transplanted Nude Mice. Pak. J. Pharm. Sci. 2021, 34, 2021–2025. [Google Scholar]
- Liu, J.; Fu, X.-Q.; Zhou, W.; Yu, H.-G.; Yu, J.-P.; Luo, H.-S. LY294002 Potentiates the Anti-Cancer Effect of Oxaliplatin for Gastric Cancer via Death Receptor Pathway. World J. Gastroenterol. WJG 2011, 17, 181–190. [Google Scholar] [CrossRef]
- Ito, H.; Yamaguchi, H.; Fujikawa, A.; Tanaka, N.; Furugen, A.; Miyamori, K.; Takahashi, N.; Ogura, J.; Kobayashi, M.; Yamada, T.; et al. A Full Validated Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometric Method for the Quantification of Oxaliplatin in Human Plasma Ultrafiltrates. J. Pharm. Biomed. Anal. 2012, 71, 99–103. [Google Scholar] [CrossRef] [PubMed]
- Ito, Y.; Kobuchi, S.; Takeda, M.; Morimoto, M. Effect of Intact Oxaliplatin in Plasma on a Cold Allodynia after Multiple Administrations in Colorectal Cancer Model Rats. Ann. Palliat. Med. 2020, 9, 3000–3006. [Google Scholar] [CrossRef] [PubMed]
- Kobuchi, S.; Kai, M.; Ito, Y. Population Pharmacokinetic Model-Based Evaluation of Intact Oxaliplatin in Rats with Acute Kidney Injury. Cancers 2021, 13, 6382. [Google Scholar] [CrossRef]
- Son, Y.J.; Kim, W.J.; Yoo, H.S. Therapeutic Applications of Electrospun Nanofibers for Drug Delivery Systems. Arch. Pharm. Res. 2014, 37, 69–78. [Google Scholar] [CrossRef]
- Abid, S.; Hussain, T.; Raza, Z.A.; Nazir, A. Current Applications of Electrospun Polymeric Nanofibers in Cancer Therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 97, 966–977. [Google Scholar] [CrossRef]
- Arnould, S.; Hennebelle, I.; Canal, P.; Bugat, R.; Guichard, S. Cellular Determinants of Oxaliplatin Sensitivity in Colon Cancer Cell Lines. Eur. J. Cancer Oxf. Engl. 2003, 39, 112–119. [Google Scholar] [CrossRef]
- Lévi, F.; Metzger, G.; Massari, C.; Milano, G. Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects. Clin. Pharmacokinet. 2000, 38, 1–21. [Google Scholar] [CrossRef]
- Seetharam, R.; Sood, A.; Goel, S. Oxaliplatin: Pre-Clinical Perspectives on the Mechanisms of Action, Response and Resistance. Ecancermedicalscience 2009, 3, 153. [Google Scholar] [CrossRef]
- Arango, D.; Wilson, A.J.; Shi, Q.; Corner, G.A.; Arañes, M.J.; Nicholas, C.; Lesser, M.; Mariadason, J.M.; Augenlicht, L.H. Molecular Mechanisms of Action and Prediction of Response to Oxaliplatin in Colorectal Cancer Cells. Br. J. Cancer 2004, 91, 1931–1946. [Google Scholar] [CrossRef] [PubMed]
- Bagheri, M.; Zandieh, M.A.; Daryab, M.; Samaei, S.S.; Gholami, S.; Rahmanian, P.; Dezfulian, S.; Eary, M.; Rezaee, A.; Rajabi, R.; et al. Nanostructures for Site-Specific Delivery of Oxaliplatin Cancer Therapy: Versatile Nanoplatforms in Synergistic Cancer Therapy. Transl. Oncol. 2024, 39, 101838. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Wang, X.; Liu, T.; Liu, S.; Jing, X. Antitumor Activity of Electrospun Polylactide Nanofibers Loaded with 5-Fluorouracil and Oxaliplatin against Colorectal Cancer. Drug Deliv. 2016, 23, 784–790. [Google Scholar] [CrossRef]
- Zhang, Z.; Liu, S.; Qi, Y.; Zhou, D.; Xie, Z.; Jing, X.; Chen, X.; Huang, Y. Time-Programmed DCA and Oxaliplatin Release by Multilayered Nanofiber Mats in Prevention of Local Cancer Recurrence Following Surgery. J. Control. Release Off. J. Control. Release Soc. 2016, 235, 125–133. [Google Scholar] [CrossRef]
- Gholipour Kanani, A.; Bahrami, S.H. Effect of Changing Solvents on Poly(ε-Caprolactone) Nanofibrous Webs Morphology. J. Nanomater. 2011, 2011, 724153. [Google Scholar] [CrossRef]
- Pourmadadi, M.; Shaghaghi, M.; Arshad, R.; Kharaba, Z.; Maleki-baladi, R.; Rahdar, A.; Fathi-karkan, S.; Pandey, S. Polymeric and Non-Polymeric Oxaliplatin Nanomedicine for Cancer Therapy: A Comprehensive Review. Eur. Polym. J. 2024, 208, 112870. [Google Scholar] [CrossRef]
- Lévi, F.; Zidani, R.; Brienza, S.; Dogliotti, L.; Perpoint, B.; Rotarski, M.; Letourneau, Y.; Llory, J.F.; Chollet, P.; Le Rol, A.; et al. A Multicenter Evaluation of Intensified, Ambulatory, Chronomodulated Chemotherapy with Oxaliplatin, 5-Fluorouracil, and Leucovorin as Initial Treatment of Patients with Metastatic Colorectal Carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999, 85, 2532–2540. [Google Scholar] [CrossRef]
- Lévi, F.; Zidani, R.; Misset, J.L. Randomised Multicentre Trial of Chronotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid in Metastatic Colorectal Cancer. International Organization for Cancer Chronotherapy. Lancet Lond. Engl. 1997, 350, 681–686. [Google Scholar] [CrossRef] [PubMed]
- Low, S.S.; Lim, C.N.; Yew, M.; Chai, W.S.; Low, L.E.; Manickam, S.; Tey, B.T.; Show, P.L. Recent Ultrasound Advancements for the Manipulation of Nanobiomaterials and Nanoformulations for Drug Delivery. Ultrason. Sonochem. 2021, 80, 105805. [Google Scholar] [CrossRef]
- Niiyama, E.; Uto, K.; Lee, C.M.; Sakura, K.; Ebara, M. Alternating Magnetic Field-Triggered Switchable Nanofiber Mesh for Cancer Thermo-Chemotherapy. Polymers 2018, 10, 1018. [Google Scholar] [CrossRef]
- Zhao, W.; Zhao, Y.; Wang, Q.; Liu, T.; Sun, J.; Zhang, R. Remote Light-Responsive Nanocarriers for Controlled Drug Delivery: Advances and Perspectives. Small Weinh. Bergstr. Ger. 2019, 15, e1903060. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sumiyama, F.; Duong, H.H.; Matsushima, H.; Matsui, K.; Yoshida, T.; Yamamoto, H.; Kosaka, H.; Sekimoto, M.; Nguyen, V.K.; Lai, T.T.; et al. Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. Nanomaterials 2025, 15, 1524. https://doi.org/10.3390/nano15191524
Sumiyama F, Duong HH, Matsushima H, Matsui K, Yoshida T, Yamamoto H, Kosaka H, Sekimoto M, Nguyen VK, Lai TT, et al. Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. Nanomaterials. 2025; 15(19):1524. https://doi.org/10.3390/nano15191524
Chicago/Turabian StyleSumiyama, Fusao, Hoang Hai Duong, Hideyuki Matsushima, Kosuke Matsui, Terufumi Yoshida, Hidekazu Yamamoto, Hisashi Kosaka, Mitsugu Sekimoto, Van Khanh Nguyen, Thanh Tung Lai, and et al. 2025. "Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models" Nanomaterials 15, no. 19: 1524. https://doi.org/10.3390/nano15191524
APA StyleSumiyama, F., Duong, H. H., Matsushima, H., Matsui, K., Yoshida, T., Yamamoto, H., Kosaka, H., Sekimoto, M., Nguyen, V. K., Lai, T. T., Ohigashi, T., Akama, T. O., Yoshii, K., Oe, E., Fujisawa, N., Ebara, M., & Kaibori, M. (2025). Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. Nanomaterials, 15(19), 1524. https://doi.org/10.3390/nano15191524